Jerold Chun, M.D., Ph.D.

Jerold Chun profile photo

Jerold Chun, M.D., Ph.D.

Senior Vice President, Neuroscience Drug Discovery


Research Assistant Professor(s)
Lab Website

Jerold Chun's Research Focus

Alzheimer's Disease, Hydrocephalus, Multiple Sclerosis
Aneuploidy, Development of Neuronal Circuits, Development and Differentiation, G-Protein Coupled Receptors, Mosaicism, Lipids, LPA, S1P, Single cell, Genome
Brain, Nervous System
  1. Genomic Mosaicism in the Brain: Genomic mosaicism (GM) is a surprising phenomenon whereby cells from the same brain actually have distinct genomes (different DNA sequences). We continue to define forms of GM, involved cell types, and GM’s impact on normal brain function and disease. Diseases of particular interest include Alzheimer’s disease, Down syndrome, Parkinson’s, and other neurodegenerative diseases as well as neuropsychiatric disorders and substance abuse.
  2. Lysophospholipid Receptor Signaling: Lysophospholipids, such as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are small fat molecules that act through G protein-coupled receptors (GPCRs) on the surface of cells. We continue to study fundamental aspects of their signaling properties, and their disease roles in hydrocephalus (water on the brain), neuropsychiatric disorders (schizophrenia, autism), and neurodegenerative disorders (multiple sclerosis, Alzheimer’s disease).
  3. Neuroscience Drug Discovery: From these and other research areas, new therapeutics for diseases of the brain are being pursued, which include identifying new targets, novel biomarkers, and mechanism-of-action studies. This approach successfully aided in the development of the first oral treatment for multiple sclerosis, fingolimod, and related lysophospholipid receptor compounds. Drug discovery efforts include not only small molecules, but also other forms of molecular therapeutics.

Jerold Chun's Bio

Professor at UCSD and TSRI

Department Head, Molecular Neuroscience, Merck Research Labs

Why do you do what you do?

I love doing science, and a chance to do some good for the world. Sanford Burnham Prebys is a great place to pursue science.
 

Education

1988-1991: Postdoctoral Fellow, Whitehead Institute/MIT, laboratories of Drs. Rudolf Jaenisch and David Baltimore, Developmental and Molecular Biology
1988: M.D., Ph.D., Stanford University School of Medicine, Neuroscience
1981: B.A., University of Hawaii at Manoa, English and Biology
 

Honors and recognition

2016: Alzheimer’s San Diego Courage and Hope Award
2014: Thomson Reuters World’s Most Influential Scientific Minds list of highly cited researchers 
2011: Killam Lecturer, Montreal Neurological Institute 
2010: Journal of Lipid Research Lecturer, Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases, Kyoto, Japan 
2007: Chancellor’s Award for Excellence in Neuroscience, LSU Medical School 
1999-2006: Independent Scientist Award, NIMH 
1994-1999: First Award, NIMH 
1993-1995: Basil O'Connor Scholar (March of Dimes Birth Defects Foundation), UCSD 
1992-1995: Klingenstein Fellow in the Neurosciences, UCSD 
1992-1994: Alfred P. Sloan Research Fellow, UCSD 
1988-1991: Helen Hay Whitney Fellow, Whitehead Institute for Biomedical Research 
1981-1988: Trainee, Medical Scientist Training Program (MSTP), Stanford University School of Medicine 


pipetting

Publications

Somatic APP gene recombination in Alzheimer's disease and normal neurons.

Lee MH, Siddoway B, Kaeser GE, Segota I, Rivera R, Romanow WJ, Liu CS, Park C, Kennedy G, Long T, Chun J

Nature 2018 Nov ;563(7733):639-645

Show All Select Publications

;

Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification.

Alioli CA, Demesmay L, Laurencin-Dalacieux S, Beton N, Farlay D, Follet H, Saber A, Duboeuf F, Chun J, Rivera R, Bouvard D, Machuca-Gayet I, Salles JP, Gennero I, Peyruchaud O

Biochim Biophys Acta Mol Cell Biol Lipids 2020 Apr 21 ;1865(8):158715

Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.

Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, Aziz NB, Elmariah S, Ngo D, Pajevic PD, Govea N, Kestenbaum BR, de Boer IH, Cheng Z, Christov M, Chun J, Leaf DE, Waikar SS, Tager AM, Gerszten RE, Thadhani RI, Clish CB, Jüppner H, Wein MN, Rhee EP

J Clin Invest 2020 Mar 2 ;130(3):1513-1526

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA<sub>1</sub>), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration.

González-Gil I, Zian D, Vázquez-Villa H, Hernández-Torres G, Martínez RF, Khiar-Fernández N, Rivera R, Kihara Y, Devesa I, Mathivanan S, Del Valle CR, Zambrana-Infantes E, Puigdomenech M, Cincilla G, Sanchez-Martinez M, Rodríguez de Fonseca F, Ferrer-Montiel AV, Chun J, López-Vales R, López-Rodríguez ML, Ortega-Gutiérrez S

J Med Chem 2020 Mar 12 ;63(5):2372-2390

LPA<sub>1/3</sub> overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction.

Lummis NC, Sánchez-Pavón P, Kennedy G, Frantz AJ, Kihara Y, Blaho VA, Chun J

Sci Adv 2019 Oct ;5(10):eaax2011

CB<sub>1</sub> and LPA<sub>1</sub> Receptors Relationship in the Mouse Central Nervous System.

González de San Román E, Manuel I, Ledent C, Chun J, Rodríguez de Fonseca F, Estivill-Torrús G, Santín LJ, Rodríguez Puertas R

Front Mol Neurosci 2019 ;12:223

Show All Publications